Thanks @Saus for your response. Appreciated.
Yes, Acadia doesn't have any rights to NNZ-2591 as yet.
Hence the reason for my post and questions.
If NNZ-2591 is safe and more effective than Trofinetide, then I makes little sense to try and run anymore costly and time consuming trials using Trofinetide.
Makes sense for Acadia to ask NEU to amend the current agreement to use NNZ-2591 or both for Fragile-z in the US ... at a cost of course.
This would also have a benefit for NEU as it would help NEU trial NNZ-2591 also, hopefully leading to a FDA approval for Fragile-X or Trofinetide.
GLTa
Share Price, page-4014
-
- There are more pages in this discussion • 7,497 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |